Objective response at week 25 was 54% with pimicotinib versus 3% with placebo, supporting robust antitumor activity in unresectable TGCT. Patient-reported endpoints showed meaningful improvements in ...
Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints and ...
Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results